ストックスクリーナーアプリを入手
314.66
3.14%
-10.45
前日終値:
$325.11
開ける：
$319.79
24時間の取引高:
138.75K
Relative Volume:
0.23
時価総額：
$8.77B
収益：
$1.77M
当期純損益:
$-123.74M
株価収益率:
-34.31
EPS:
-9.17
ネットキャッシュフロー:
$-95.21M
1週間 パフォーマンス:
-7.51%
1か月 パフォーマンス:
+3.04%
6か月 パフォーマンス:
+572.18%
1年 パフォーマンス:
+732.01%
1日の値動き範囲:
$311.42
$320.71
1週間の範囲:
$311.42
$342.51
52週間の値動き範囲:
$26.70
$356.00
Praxis Precision Medicines Inc Stock (PRAX) Company Profile
名前
Praxis Precision Medicines Inc
セクター
電話
617-300-8460
住所
99 HIGH STREET, 30TH FLOOR, BOSTON
Compare PRAX vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PRAX
Praxis Precision Medicines Inc
|
314.72 | 9.05B | 1.77M | -123.74M | -95.21M | -9.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.11 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
763.98 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
725.91 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.11 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.83 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Praxis Precision Medicines Inc Stock (PRAX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-02-02 | 開始されました | Wells Fargo | Equal Weight |
| 2025-12-15 | 繰り返されました | Oppenheimer | Outperform |
| 2025-11-19 | 開始されました | BTIG Research | Buy |
| 2025-06-02 | 再開されました | Oppenheimer | Outperform |
| 2025-05-07 | 開始されました | Chardan Capital Markets | Buy |
| 2025-03-03 | 繰り返されました | H.C. Wainwright | Buy |
| 2025-02-11 | 開始されました | Deutsche Bank | Buy |
| 2024-08-05 | 開始されました | Oppenheimer | Outperform |
| 2024-06-24 | 開始されました | Needham | Buy |
| 2024-06-18 | 開始されました | Guggenheim | Buy |
| 2024-05-01 | 開始されました | Robert W. Baird | Outperform |
| 2023-09-19 | 開始されました | Truist | Buy |
| 2022-06-06 | ダウングレード | Wedbush | Outperform → Neutral |
| 2021-12-16 | 開始されました | H.C. Wainwright | Buy |
| 2021-08-26 | 開始されました | BofA Securities | Buy |
| 2021-04-26 | 開始されました | William Blair | Outperform |
| 2020-11-11 | 開始されました | Wedbush | Outperform |
| 2020-11-10 | 開始されました | Cowen | Outperform |
| 2020-11-10 | 開始されました | Evercore ISI | Outperform |
| 2020-11-10 | 開始されました | Piper Sandler | Overweight |
すべてを表示
Praxis Precision Medicines Inc (PRAX) 最新ニュース
Praxis Precision Medicines, Inc. $PRAX Shares Sold by TD Asset Management Inc - MarketBeat
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
A Look At Praxis Precision Medicines (PRAX) Valuation After Wider Full Year And Q4 Net Loss - simplywall.st
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Biotech Praxis gives 2,931 stock units to 14 new employees - Stock Titan
PRAX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Praxis Eyes Blockbuster Future As Precision Neurology Pipeline Matures - Citeline News & Insights
Why (PRAX) Price Action Is Critical for Tactical Trading - Stock Traders Daily
GSA Capital Partners LLP Trims Stock Position in Praxis Precision Medicines, Inc. $PRAX - MarketBeat
Praxis Precision Medicines, Inc (PRAX) Stock Analysis: A Biotech Powerhouse with 76% Upside Potential - DirectorsTalk Interviews
How Investors Are Reacting To Praxis (PRAX) Wider Losses, Fresh NDAs And Multi‑Year Cash Runway - simplywall.st
PRAX Should I Buy - Intellectia AI
Praxis Precision Medicines (NASDAQ:PRAX) Raised to Strong-Buy at Wolfe Research - MarketBeat
Wolfe Research initiates coverage of Praxis Precision Medicines (PRAX) with outperform recommendation - MSN
Assessing Praxis Precision Medicines (PRAX) Valuation After Strong Recent Share Price Momentum - simplywall.st
Wolfe Research initiates Praxis stock with outperform rating - Investing.com
Wolfe Research initiates Praxis stock with outperform rating By Investing.com - Investing.com India
Investor Buys Up $81 Million in Praxis Stock as Shares Soar Over 300% in One Year - AOL.com
Wolfe Research Initiates Coverage of Praxis Precision Medicines (PRAX) with Outperform Recommendation - Nasdaq
Wolfe Research Initiates Coverage on Praxis Precision Medicine (PRAX) | PRAX Stock News - GuruFocus
A Look At Praxis Precision Medicines (PRAX) Valuation After Recent Share Price Momentum - Yahoo Finance
3,826 Shares in Praxis Precision Medicines, Inc. $PRAX Purchased by ProShare Advisors LLC - MarketBeat
Praxis NDAs And FDA Designations Put Focus On Valuation Upside - Yahoo! Finance Canada
Perceptive Advisors Acquires 431,432 Shares of Praxis Precision Medicines - Intellectia AI
Praxis Precision Medicines Maps Aggressive Path to Market - TipRanks
Praxis Stock Surges 320% as One Biotech Investor's Buy Pushes Stake to Nearly $600 Million - Yahoo Finance
Praxis Stock Surges 320% as One Biotech Investor's Buy Pushes Stake to Nearly $600 Million - The Motley Fool
Biotech Stock Up 266%: This New $55 Million Bet Signals Conviction in Praxis Amid Pipeline Progress - AOL.com
Praxis Medicines Q4 2025 Earnings Call Transcript - AOL.com
Praxis Precision Medicines (NASDAQ:PRAX) Sets New 12-Month High Following Analyst Upgrade - Defense World
PRAX Stock: Wells Fargo Raises Price Target to $305 | PRAX Stock News - GuruFocus
Praxis Precision shares rally on price target hikes: Analyst sees upside as high as 100% for stock - MSN
Praxis Precision Shares Rally On Price Target Hikes: Analyst Sees Upside As High As 100% For Stock - Asianet Newsable
Praxis Precision Medicines stock reaches 52-week high at 337.01 USD - Investing.com
Baird Raises Price Target for PRAX to $433, Maintains Outperform Rating | PRAX Stock News - GuruFocus
Praxis Precision Medicine Analysts Raise Their Forecasts After Q4 Results - Benzinga
Praxis Precision Medicines Stock Surges on FDA Momentum - TipRanks
Praxis Precision Medicines (NASDAQ:PRAX) Sets New 1-Year High Following Analyst Upgrade - MarketBeat
Truist Financial Forecasts Strong Price Appreciation for Praxis Precision Medicines (NASDAQ:PRAX) Stock - MarketBeat
Wedbush Raises Price Target on Praxis Precision Medicines to $130 From $95, Keeps Underperform Rating - marketscreener.com
Truist Boosts Price Target on Praxis Precision Medicines to $700 From $500, Keeps Buy Rating - marketscreener.com
Deutsche Bank Raises Price Target on Praxis Precision Medicines to $412 From $357, Keeps Buy Rating - marketscreener.com
Wedbush Raises Price Target for PRAX to $130 Despite 'Underperfo - GuruFocus
Wedbush Issues Positive Forecast for Praxis Precision Medicines (NASDAQ:PRAX) Stock Price - MarketBeat
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Q4 2025 Earnings Call Transcript - Insider Monkey
Praxis Precision Medicines, Inc (PRAX) Stock Analysis: A Biotech Pioneer with an 80.92% Potential Upside - DirectorsTalk Interviews
Praxis Therapeutics: Advancing Late-Stage Neurology Pipeline Toward Commercialization with Multibillion-Dollar Market Potential - TipRanks
Earnings call transcript: Praxis Precision Q4 2025 misses EPS forecast By Investing.com - Investing.com Canada
Decoding Praxis Precision Medicines Inc (PRAX): A Strategic SWOT Insight - GuruFocus
Praxis Precision Medicines, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Praxis Precision Medicines Inc (PRAX) Q4 2025 Earnings Call Highlights: Strong Financial ... By GuruFocus - Investing.com Canada
Praxis Precision Medicines Inc (PRAX) 財務データ
収益
当期純利益
現金流量
EPS
Praxis Precision Medicines Inc (PRAX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Nemiroff Alex | General Counsel and Secretary |
Nov 20 '25 |
Sale |
193.09 |
25,130 |
4,852,256 |
20,832 |
| Mastrocola Lauren | Principal Accounting Officer |
Nov 20 '25 |
Option Exercise |
61.12 |
13,600 |
831,257 |
24,042 |
| Mastrocola Lauren | Principal Accounting Officer |
Nov 20 '25 |
Sale |
192.08 |
13,600 |
2,612,244 |
10,442 |
4.20%
大文字化:
|
ボリューム (24 時間):